Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge.

A composite computational model of liver glucose homeostasis. I. Building the composite model. J R Soc Interface (2011) 0.92

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System. Diabetes Care (2015) 0.81

A composite computational model of liver glucose homeostasis. II. Exploring system behaviour. J R Soc Interface (2012) 0.79

Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases. Toxicol Pathol (2010) 1.45

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs (2013) 0.99

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2012) 0.95

The intravenous glucose tolerance test in cannulated Wistar rats: a robust method for the in vivo assessment of glucose-stimulated insulin secretion. J Pharmacol Toxicol Methods (2008) 0.94

Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol (2004) 0.93

Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol (2011) 0.87

The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle. J Physiol (2002) 0.87

Acetyl group availability influences phosphocreatine degradation even during intense muscle contraction. J Physiol (2004) 0.87

The glycogenic action of protein targeting to glycogen in hepatocytes involves multiple mechanisms including phosphorylase inactivation and glycogen synthase translocation. J Biol Chem (2004) 0.86

Acetyl-CoA provision and the acetyl group deficit at the onset of contraction in ischemic canine skeletal muscle. Am J Physiol Endocrinol Metab (2004) 0.85

Manganese enhancement in non-CNS organs. NMR Biomed (2010) 0.83

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med (2012) 0.81

The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle. J Physiol (2002) 0.78

Increased sensitivity of glycogen synthesis to phosphorylase-a and impaired expression of the glycogen-targeting protein R6 in hepatocytes from insulin-resistant Zucker fa/fa rats. FEBS J (2006) 0.77

Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes. J Pharmacol Toxicol Methods (2010) 0.77

Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy. J Pharmacol Toxicol Methods (2006) 0.77

Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle. Exp Physiol (2002) 0.75